Page last updated: 2024-09-05

tolvaptan and Disease Exacerbation

tolvaptan has been researched along with Disease Exacerbation in 60 studies

Research

Studies (60)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (5.00)	29.6817
2010's	41 (68.33)	24.3611
2020's	16 (26.67)	2.80

Authors

Authors	Studies
Caprara, C; Corradi, V; Gastaldon, F; Giuliani, A; Marcello, M; Marturano, D; Rigato, M; Ronco, C; Zanella, M	1
Agraz-Pamplona, I; Alvarez, C; Álvarez-Mora, MI; Bastida, C; Blasco, M; Broseta, JJ; Furlano, M; Nicolau, C; Piñeiro, GJ; Poch, E; Quintana, LF; Rodríguez-Espinosa, D; Ruiz, C; Sánchez-Baya, M; Torra-Balcells, R	1
Barnett, CL; Mader, G; Mladsi, D; Oberdhan, D; Purser, M; Sanon, M; Seliger, S; Watnick, T	1
Hashimoto, M; Higashiura, A; Honda, M; Iijima, H; Iwasaki, A; Kiriki, M; Nagasawa, Y; Nishimura, T; Tada, T; Yamakado, K	1
Quiroga, B; Torra, R	1
Cho, H; Kim, H; Kim, YC; Kim, YH; Lee, MK; Lee, YS; Min, HS; Shin, JH; Shin, TY	1
Davenport, E; Fernandes, AW; Krasa, HB; Lioudis, M; Nunna, S; Oberdhan, D; Zhou, X	1
Fenton, RA; Gansevoort, RT; Geurts, F; Hoorn, EJ; Kramers, BJ; Meijer, E; Salih, M; Xue, L; Zietse, R	1
Auber, B; Haller, H; Schmitt, R; Wulfmeyer, VC	1
Chen, M; Gu, J; Hu, S; Li, D; Tan, X; Zhang, X	1
Bange, H; Dijkstra, KL; Kanhai, AA; Leonhard, WN; Peters, DJM; Price, LS; Verburg, L	1
Chakraborty, R; DeCoy, ME; Kline, T; Raina, R	1
Bovy, C; Delanaye, P; Jouret, F; Krzesinski, JM	1
Amicone, M; Angelucci, V; Pisani, A; Riccio, E	1
Fukuhara, H; Furukawa, T; Higashihara, E; Horie, S; Kaname, S; Kawano, H; Muto, S; Taguchi, S; Tambo, M; Yamaguchi, T; Yokoyama, K; Yoshioka, T	1
Collard, L; Dachy, A; Ghuysen, MS; Jouret, F; Krzesinski, JM; Mekahli, D; Seghaye, MC	1
Bonny, O; Martin, PY; Stucker, F	1
Chebib, FT; Torres, VE	1
Torres, VE; van Gastel, MDA	1
Isobe, M; Kamiyama, M; Masumura, M; Nomoto, H; Ohno, M; Oumi, T; Sakakibara, A; Satoh, Y; Sugiyama, T; Suzuki, M; Takahashi, Y; Yabe, K; Yamashita, S	1
Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M	1
Koch, M; Schulz, C; Utpatel, K	1
Blais, JD; Chapman, AB; Cornec-Le Gall, E; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Harris, PC; Heyer, CM; Irazabal, MV; Le Meur, Y; Ouyang, J; Perrone, RD; Senum, SR; Torres, VE	1
Hamada, M; Ikeda, S; Kadota, H; Miyazaki, S; Ogimoto, A; Ohshima, K; Shimizu, H	1
Andreisek, G; Kistler, AD	1
Bennett Wilton, H; Cabrera, MV; McEwan, P; O'Reilly, K; Ong, ACM; Robinson, P; Sandford, R; Scolari, F; Walz, G; Ørskov, B	1
Chapman, AB; Chebib, FT; Dahl, NK; Harris, PC; Mrug, M; Mustafa, RA; Perrone, RD; Rastogi, A; Torres, VE; Watnick, T; Yu, ASL	1
Ars, E; Ayasreh, N; Ballarín, J; Bullich, G; Furlano, M; Loscos, I; Martí, T; Rius, A; Roca, L; Torra, R	1
Hiramatsu, E; Ito, C; Otsuka, Y; Shinjo, H; Takeda, A; Tanaka, A; Watanabe, Y	1
Blair, HA	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Higashihara, E; Lee, J; Ouyang, J; Perrone, RD; Stade, K; Torres, VE; van Gastel, MDA	1
Bennett, H; Hamilton, K; McEwan, P; O'Reilly, K	1
Gaur, P; Gedroyc, W; Hill, P	1
Bankir, L; Bichet, DG	1
Bankir, L; Bouby, N; Ritz, E	1
Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A	1
Ambrosy, AP; Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Konstam, MA; Maggioni, AP; Mentz, RJ; Nodari, S; Subacius, H; Vaduganathan, M	1
Casscells, SW; Gheorghiade, M; Maggioni, AP; Miller, AB; Pang, PS; Payvar, S; Reid, KJ; Spertus, JA; Swedberg, K; Zannad, F	1
Chertow, GM; Erickson, KF; Goldhaber-Fiebert, JD	1
Bellevicine, C; Bisesti, V; Buonocore, P; Cappellaio, F; De Falco, V; Federico, S; Pisani, A; Riccio, E; Russo, L; Sabbatini, M; Troncone, G	1
Baur, BP; Meaney, CJ	1
Boertien, WE; Czerwiec, FS; de Jong, PE; Engels, GE; Gansevoort, RT; Kappert, P; Krasa, HB; Meijer, E; Oberdhan, D; Ouyang, J; Renken, RJ; Struck, J; ter Horst, GJ; van der Jagt, EJ; van Oeveren, W	1
Higashihara, E; Horie, S; Kawano, H; Matsuzaki, T; Muto, S; Narita, I; Ouyang, J; Torres, VE; Ubara, Y	1
Blau, W; Brock, J; Gattenlöhner, S; Karrasch, T; Nilles, M; Roller, FC; Roller, FF; Schäffler, A; Steiner, D	1
Buemi, M; Cernaro, V; Pellicanò, V; Santoro, D; Trifirò, G; Visconti, L	1
Schumacher, B	1
Simms, RJ	1
Arici, M; Benzing, T; Birn, H; Capasso, G; Covic, A; Devuyst, O; Drechsler, C; Eckardt, KU; Emma, F; Gansevoort, RT; Knebelmann, B; Le Meur, Y; Massy, ZA; Ong, AC; Ortiz, A; Schaefer, F; Torra, R; Van Biesen, W; Vanholder, R; Więcek, A; Zoccali, C	1
Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Grantham, JJ; Higashihara, E; Ouyang, J; Perrone, RD; Torres, VE	1
Ambrosy, AP; Butler, J; Gheorghiade, M; Katz, SD; Konstam, MA; Mecklai, A; Subačius, H	1
Banach, M; Bartnicki, P; Franczyk, B; Gluba-Brzózka, A; Rysz, J	1
Caprara, C; Corradi, V; Ferrari, F; Gastaldon, F; Giuliani, A; Martino, F; Ronco, C	1
Blair, JE; Burnett, JC; Chen, CF; Gheorghiade, M; Grinfeld, L; Khan, S; Konstam, MA; Maggioni, AP; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, CA	1
Allen, LA; Chan, PS; Dunlay, SM; Gheorghiade, M; Hauptman, PJ; Konstam, MA; Maggioni, AP; Reid, KJ; Spertus, JA; Swedberg, K; Zannad, F	1
Bae, K; Chapman, AB; Czerwiec, FS; Grantham, JJ; Higashihara, E; Horie, S; Krasa, HB; Nutahara, K; Ouyang, J; Torres, VE; Watnick, TJ	1
Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y	1
Bonow, RO; Fought, AJ; Gheorghiade, M; Huffman, M; Konstam, M; Kwasny, MJ; Maggioni, AP; Mentz, RJ; Nodari, S; Sarma, S; Subacius, H; Swedberg, K; Zannad, F	1
Goldsmith, SR	1
Adams, KF; Barbagelata, A; Elkayam, U; Gattis, WA; Gheorghiade, M; O'Connor, CM; Orlandi, C	1

Reviews

16 review(s) available for tolvaptan and Disease Exacerbation

Article	Year
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression. Nutrients, 2022, Nov-03, Volume: 14, Issue:21 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan	2022
[Therapeutic innovation in nephrology : 10 years of progress]. Revue medicale de Liege, 2020, Volume: 75, Issue:5-6 Topics: Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Nephrology; Quality of Life; Renal Insufficiency, Chronic; Tolvaptan	2020
[Clinical use of tolvaptan: a 2021 review]. Revue medicale suisse, 2021, Feb-24, Volume: 17, Issue:727 Topics: Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Inappropriate ADH Syndrome; Tolvaptan	2021
Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021, Volume: 78, Issue:2 Topics: Age Factors; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Magnetic Resonance Imaging; Organ Size; Polycystic Kidney, Autosomal Dominant; Risk Assessment; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography	2021
Polycystic Kidney Disease and the Vasopressin Pathway. Annals of nutrition & metabolism, 2017, Volume: 70 Suppl 1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Vasopressins	2017
Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. Praxis, 2018, Volume: 107, Issue:3 Topics: Adolescent; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diagnostic Imaging; Disease Progression; Drug Approval; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Kidney Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Prognosis; Receptors, Vasopressin; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography; Young Adult	2018
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:10 Topics: Algorithms; Antidiuretic Hormone Receptor Antagonists; Clinical Protocols; Dehydration; Disease Progression; Diuresis; Female; Glomerular Filtration Rate; Humans; Liver; Magnetic Resonance Imaging; Male; Patient Selection; Polycystic Kidney, Autosomal Dominant; Time Factors; Tolvaptan; Treatment Outcome	2018
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs, 2019, Volume: 79, Issue:3 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Dose-Response Relationship, Drug; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Tolvaptan; Treatment Outcome	2019
ADPKD-what the radiologist should know. The British journal of radiology, 2019, Volume: 92, Issue:1098 Topics: Antidiuretic Hormone Receptor Antagonists; Carcinoma, Renal Cell; Cysts; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Kidney Calculi; Kidney Neoplasms; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Vasopressin: a novel target for the prevention and retardation of kidney disease? Nature reviews. Nephrology, 2013, Volume: 9, Issue:4 Topics: Animals; Benzazepines; Disease Progression; Humans; Hypertension, Renal; Incidence; Prevalence; Renal Insufficiency, Chronic; Tolvaptan; Vasopressins	2013
Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy, 2014, Volume: 34, Issue:6 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Humans; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan	2014
An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:9 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Drug Design; Drugs, Investigational; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2015
Autosomal dominant polycystic kidney disease. BMJ (Clinical research ed.), 2016, Feb-11, Volume: 352 Topics: Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Risk Factors; Tolvaptan	2016
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Europe; Humans; Hyponatremia; Polycystic Kidney, Autosomal Dominant; Societies, Medical; Tolvaptan	2016
Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:15 Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Disease Progression; Drug Therapy, Combination; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan; TOR Serine-Threonine Kinases	2016
Predictors of rapid disease progression in autosomal dominant polycystic kidney disease. Minerva medica, 2017, Volume: 108, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Clinical Trials as Topic; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Organ Size; Polycystic Kidney, Autosomal Dominant; Renin-Angiotensin System; Retrospective Studies; Tolvaptan; TRPP Cation Channels	2017

Trials

15 trial(s) available for tolvaptan and Disease Exacerbation

Article	Year
Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatric research, 2021, Volume: 89, Issue:4 Topics: Adolescent; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Liver; Male; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Risk; Tolvaptan; Treatment Outcome; Young Adult	2021
Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan. International heart journal, 2017, Aug-03, Volume: 58, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Electric Impedance; Female; Follow-Up Studies; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Prognosis; Renal Insufficiency; Retrospective Studies; Tolvaptan	2017
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 04-01, Volume: 33, Issue:4 Topics: Adolescent; Adult; Age Factors; Antidiuretic Hormone Receptor Antagonists; Clinical Trials as Topic; Disease Progression; Female; Gene Rearrangement; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Severity of Illness Index; Tolvaptan; TRPP Cation Channels; Young Adult	2018
A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC nephrology, 2018, 02-13, Volume: 19, Issue:1 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Models, Theoretical; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Tolvaptan; Treatment Outcome	2018
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney international, 2019, Volume: 96, Issue:1 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Glycopeptides; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Tolvaptan; Treatment Outcome; Young Adult	2019
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC nephrology, 2019, 04-23, Volume: 20, Issue:1 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Management; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Polycystic Kidney, Autosomal Dominant; Proof of Concept Study; Reproducibility of Results; Time; Tolvaptan	2019
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. European journal of heart failure, 2013, Volume: 15, Issue:12 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hematocrit; Hospitalization; Humans; Kidney Function Tests; Male; Middle Aged; Natriuretic Peptides; Outcome Assessment, Health Care; Prognosis; Renal Insufficiency; Stroke Volume; Survival Analysis; Tolvaptan	2013
Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. European journal of heart failure, 2013, Volume: 15, Issue:12 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Temperature; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Risk Assessment; Stroke Volume; Survival Analysis; Tolvaptan	2013
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clinical and experimental nephrology, 2015, Volume: 19, Issue:5 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Asian People; Benzazepines; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Japan; Kidney; Liver Function Tests; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Young Adult	2015
[Cystic kidneys can now be treated]. MMW Fortschritte der Medizin, 2015, Sep-10, Volume: 157, Issue:15 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cohort Studies; Disease Progression; Double-Blind Method; Drug Approval; Germany; Humans; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Tolvaptan	2015
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clinical journal of the American Society of Nephrology : CJASN, 2016, 05-06, Volume: 11, Issue:5 Topics: Adult; Albuminuria; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypernatremia; Hypertension; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pain; Polycystic Kidney, Autosomal Dominant; Severity of Illness Index; Tolvaptan	2016
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. European heart journal, 2009, Volume: 30, Issue:13 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Epidemiologic Methods; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Readmission; Prognosis; Tolvaptan; Treatment Outcome; Weight Gain	2009
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:10 Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Female; Glomerular Filtration Rate; Hormone Antagonists; Humans; Japan; Kidney; Male; Middle Aged; North America; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Time Factors; Tolvaptan; Treatment Outcome; Young Adult	2011
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. European journal of heart failure, 2013, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Combined Modality Therapy; Comorbidity; Cross-Sectional Studies; Diabetes Complications; Diet, Diabetic; Disease Progression; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Patient Discharge; Proportional Hazards Models; Tolvaptan; Treatment Outcome	2013
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American heart journal, 2003, Volume: 145, Issue:2 Suppl Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Double-Blind Method; Heart Failure; Hospitalization; Humans; Patient Selection; Prospective Studies; Receptors, Vasopressin; Research Design; Tolvaptan	2003

Other Studies

29 other study(ies) available for tolvaptan and Disease Exacerbation

Article	Year
[Slowing progression of chronic kidney disease in polycistic kidney disease patients with tolvaptan: from guidelines to clinical practice]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2021, Oct-26, Volume: 38, Issue:5 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan	2021
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment. Nephron, 2023, Volume: 147, Issue:3-4 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC nephrology, 2022, 10-18, Volume: 23, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Time Factors; Tolvaptan	2022
Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease. Journal of medical ultrasonics (2001), 2023, Volume: 50, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Ultrasonography	2023
Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease. Investigative and clinical urology, 2023, Volume: 64, Issue:3 Topics: Artificial Intelligence; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC nephrology, 2023, 06-22, Volume: 24, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2023
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clinical journal of the American Society of Nephrology : CJASN, 2023, 11-01, Volume: 18, Issue:11 Topics: Antidiuretic Hormone Receptor Antagonists; Dinoprostone; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Kidney; Male; Osmoregulation; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency; Tolvaptan	2023
Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients. American journal of nephrology, 2019, Volume: 50, Issue:4 Topics: Adult; Aged; Algorithms; Disease Progression; Female; Genotype; Germany; Glomerular Filtration Rate; Humans; Kidney Function Tests; Magnetic Resonance Imaging; Male; Middle Aged; Nephrology; Patient Selection; Polycystic Kidney, Autosomal Dominant; Retrospective Studies; Tolvaptan; Tomography, X-Ray Computed; Young Adult	2019
[Research progress in autosomal dominant polycystic kidney disease]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2019, Oct-28, Volume: 44, Issue:10 Topics: Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. Scientific reports, 2020, 02-03, Volume: 10, Issue:1 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Culture Techniques; Combined Modality Therapy; Cysts; Disease Progression; Humans; Kidney; Male; Mice; Pioglitazone; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Rats; Rats, Wistar; Tolvaptan	2020
[Tolvaptan in ADPKD: a turning point or an unsustainable therapy? One year of "real life" experience]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2020, Jun-10, Volume: 37, Issue:3 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Medication Adherence; Middle Aged; Patient Satisfaction; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Quality of Life; Time Factors; Tolvaptan; Young Adult	2020
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. American journal of nephrology, 2020, Volume: 51, Issue:11 Topics: Adult; Aged; Body Height; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Patient Selection; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Reference Values; Retrospective Studies; Risk Assessment; ROC Curve; Severity of Illness Index; Time Factors; Tolvaptan	2020
[Autosomal dominant polycystic kidney disease : a pediatric perspective]. Revue medicale de Liege, 2020, Volume: 75, Issue:12 Topics: Adult; Animals; Child; Disease Progression; Humans; Kidney; Kidney Failure, Chronic; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World journal of gastroenterology, 2017, Aug-07, Volume: 23, Issue:29 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Spironolactone; Tolvaptan; Treatment Outcome	2017
[Hyponatremia in a 58-year-old female patient with EGFR-positive lung adenocarcinoma]. Der Internist, 2018, Volume: 59, Issue:4 Topics: Adenocarcinoma of Lung; Afatinib; Biopsy; Bronchoscopy; Cell Transformation, Neoplastic; Disease Progression; DNA Mutational Analysis; DNA-Binding Proteins; ErbB Receptors; Female; Humans; Hyponatremia; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paraneoplastic Syndromes; Small Cell Lung Carcinoma; Tolvaptan; Tomography, X-Ray Computed; Transcription Factors	2018
Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. ESC heart failure, 2017, Volume: 4, Issue:4 Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan; Treatment Outcome	2017
Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression. American journal of nephrology, 2018, Volume: 48, Issue:4 Topics: Adult; Age Factors; Algorithms; Antidiuretic Hormone Receptor Antagonists; Clinical Decision-Making; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Patient Selection; Polycystic Kidney, Autosomal Dominant; Predictive Value of Tests; Retrospective Studies; Tolvaptan; Ultrasonography	2018
Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2019, Volume: 23, Issue:4 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Comorbidity; Disease Progression; Female; Heart Failure; Hospitalization; Humans; Japan; Kidney Function Tests; Male; Outcome and Process Assessment, Health Care; Renal Dialysis; Renal Insufficiency, Chronic; Time; Time-to-Treatment; Tolvaptan	2019
What can copeptin tell us in patients with autosomal dominant polycystic disease? Kidney international, 2019, Volume: 96, Issue:1 Topics: Disease Progression; Glycopeptides; Humans; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2019
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine	2013
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Annals of internal medicine, 2013, Sep-17, Volume: 159, Issue:6 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Benzazepines; Cost-Benefit Analysis; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Life Expectancy; Male; Markov Chains; Middle Aged; Polycystic Kidney, Autosomal Dominant; Quality-Adjusted Life Years; Tolvaptan	2013
Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. American journal of physiology. Renal physiology, 2014, May-15, Volume: 306, Issue:10 Topics: Animals; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Kidney; Male; MAP Kinase Signaling System; Polycystic Kidney Diseases; Rats; Rats, Inbred Strains; Rats, Mutant Strains; Rats, Sprague-Dawley; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; Treatment Outcome	2014
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:6 Topics: Acute Kidney Injury; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glomerular Filtration Rate; Glycopeptides; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Tolvaptan; Treatment Outcome	2015
[77-year-old female with hyponatremia, pruritus and papulous exanthema]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Diagnosis, Differential; Disease Progression; Exanthema; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lymphoma, T-Cell, Cutaneous; Multimodal Imaging; Paraneoplastic Syndromes; Positron-Emission Tomography; Pruritus; Tolvaptan; Tomography, X-Ray Computed	2015
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC. Heart failure, 2016, Volume: 4, Issue:7 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cause of Death; Disease Progression; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mortality; Patient Readmission; Proportional Hazards Models; Randomized Controlled Trials as Topic; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome	2016
Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. European journal of heart failure, 2010, Volume: 12, Issue:4 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Confidence Intervals; Disease Progression; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Discharge; Patient Readmission; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires; Time Factors; Tolvaptan; Treatment Outcome; United States	2010
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circulation. Heart failure, 2012, Jul-01, Volume: 5, Issue:4 Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left	2012
Hyponatremia and outcomes in patients with heart failure. Heart (British Cardiac Society), 2012, Volume: 98, Issue:24 Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Global Health; Heart Failure; Humans; Hyponatremia; Incidence; Prognosis; Sodium; Survival Rate; Tolvaptan	2012
[Heart failure. Can vasopressin antagonists improve the prognosis?]. MMW Fortschritte der Medizin, 2003, Nov-27, Volume: 145, Issue:48 Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials, Phase II as Topic; Disease Progression; Heart Failure; Humans; Survival Rate; Tolvaptan; Water-Electrolyte Balance	2003